

Health market

| CURRANT ASSESSMENT |

- The health services are one of the most important fields of the German economy and that does not only apply to Germany.
- The overall expenses of the German health service summed up to 239 billion in the year 2005 which is 11% of GDP.
- A study (2005) of Roland Berger Strategy Consultants estimates a 70 %- growth of the health market until the year 2020.
- But the actual size of the German health system including all fields beyond the outpatient and in-patient sector is estimated to sum up to 500 billion euros.
- Since the mid nineties, the health service sector has grown approximately 1 percentage faster than the overall German economy.
- About 4.3 million people work in the German health service - 10% of the overall labour force



Contact information

- There are various ways how you can invest in SANEMUS AG.
- If you have further questions, please do not hesitate to contact us:

Dipl.-Kfm., Dipl.-Psych. Michael Thiess
CEO

Dipl.-Kffr. Astrid Heilmair
Investment Manager

Dipl.-Pflegerin (FH) Juliane Quaranta
Investment Manager

Dipl.-Kfm. Torsten Schindler
Investment Manager

Hans-Dieter Falkenberg
Investment Manager

Dipl.-Kfm. Christoph Weideneder
Chairman



Frauenstraße 12 (Viktualienmarkt)
D-80331 München

Tel.: +49 (0)89 1 89 44 89 - 0
Fax: +49 (0)89 1 89 44 89 - 39
E-Mail: info@sanemus.com
www.sanemus.com

Commercial Register Munich 16 20 43
Trade ID: DE 248 168 367



| BUSINESS PHILOSOPHY |

- SANEMUS AG was established by experienced professionals with backgrounds in the healthcare- and financial market. SANEMUS is one of the few German Private Equity Companies which focusses on investing in corporate assets within the healthcare market.
- Investors get the chance to directly participate in the sustainable growth of the healthcare system.
- Companies with new and innovative business models are enabled to finance their growth potentials.
- As far as we hold a stake in a company, we actively contribute our trade experience and therefore open up new development perspectives.



Investor Relations

| INVESTMENT PHILOSOPHY |

- Preferably, the associate companies already successfully completed their start-up period and offers ready for the market products and services
- Investment in new start-up companies is possible, as far as the business model is within the field of the new demands and opportunities of the health market.



| TARGET LINES |

- **Life Sciences** (biology, chemistry, human medicine, medical engineering, etc.)
- **Healthcare** (hospitals, clinics, nursing homes, out-patient sector, trade with pharmaceutical- and health products, etc.)

Portfolio

| INVESTMENT MANAGEMENT |

- SANEMUS AG mainly invests in companies which offer majority interest, but we also consider minority interest.
- The objective of the investment management is to increase our investment by intensive consultation, by taking over executive positions and by using the available network extensively.
- SANEMUS AG is not obliged to sell its investment after a certain time. We rather focus on keeping the investment in our portfolio. We are sure that this is a good way for SANEMUS AG to profit from the sustainable growth within the health market.



Corporate Governance

As far as the health market, finance and sciences are concerned, we are supported by our extensive network:

| INVESTMENT COMMITTEE |

- **Hans Milo Halhuber**
CEO
Conmit Finance GmbH, Grünwald
- **Univ. Prof. Dr. med. Andreas B. Imhoff**
Professor for orthopaedics and orthopaedic surgery
Chairman of the division sports orthopäedics
Technische Universität München,
Klinikum Rechts der Isar

| BODY OF EXPERTS |

- **Dr. Axel Cronauer**
Managing Partner
CBP, Consulting Engineers GmbH, Munich
- **Dr. Dr. med. Michael. W. Dahm**
Managing Director
Hexal Gentech ForschungsGmbH,
Holzkirchen
- **Stephan Wehselau**
CFO / Managing Director
JenaValve Technology GmbH, Munich

And more experienced personalities will be joining in shortly.